Development and validation of an HPLC–MS/MS method to determine clopidogrel in human plasma  by Liu, Gangyi et al.
Institute of Materia Medica, Chinese Academy of Medical SciencesChinese Pharmaceutical Association
www.elsevier.com/locate/apsb
Acta Pharmaceutica Sinica B
Acta Pharmaceutica Sinica B 2016;6(1):55–63http://dx.doi.org/10.10
2211-3835 & 2016 Ch
Elsevier B.V. This is
Abbreviations: ESI,
quantiﬁcation; MRM,
nCorresponding auth
E-mail address: c
Peer review under rwww.sciencedirect.comORIGINAL ARTICLEDevelopment and validation of an HPLC–MS/MS
method to determine clopidogrel in human plasmaGangyi Liua, Chunxia Donga, Weiwei Shena, Xiaopei Lua,
Mengqi Zhanga, Yuzhou Guib, Qinyi Zhoua, Chen Yua,naCentral Laboratory, Shanghai Clinical Center, Chinese Academy of Sciences/Central Laboratory, Shanghai Xuhui
Central Hospital, Shanghai 200031, China
bState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Science,
Shanghai 200233, China
Received 10 June 2015; received in revised form 9 November 2015; accepted 13 November 2015KEY WORDS
Clopidogrel;
Online-SPE;
LC–MS/MS;
Back-conversion;
Bioequivalence;
Deuterated analogue;
Real samples stability;
FDA guidelines16/j.apsb.2015.11.00
inese Pharmaceutica
an open access artic
electrospray ionizat
multiple reaction m
or. Tel.: þ86 21 54
hen-yu@online.sh.cn
esponsibility of InstAbstract A quantitative method for clopidogrel using online-SPE tandem LC–MS/MS was developed
and fully validated according to the well-established FDA guidelines. The method achieves adequate
sensitivity for pharmacokinetic studies, with lower limit of quantiﬁcations (LLOQs) as low as 10 pg/mL.
Chromatographic separations were performed on reversed phase columns Kromasil Eternity-2.5-C18-
UHPLC for both methods. Positive electrospray ionization in multiple reaction monitoring (MRM) mode
was employed for signal detection and a deuterated analogue (clopidogrel-d4) was used as internal
standard (IS). Adjustments in sample preparation, including introduction of an online-SPE system proved
to be the most effective method to solve the analyte back-conversion in clinical samples. Pooled clinical
samples (two levels) were prepared and successfully used as real-sample quality control (QC) in the
validation of back-conversion testing under different conditions. The result showed that the real samples
were stable in room temperature for 24 h. Linearity, precision, extraction recovery, matrix effect on spiked
QC samples and stability tests on both spiked QCs and real sample QCs stored in different conditions met
the acceptance criteria. This online-SPE method was successfully applied to a bioequivalence study of
75 mg single dose clopidogrel tablets in 48 healthy male subjects.
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Clopidogrel, frequently used with aspirin, is an oral antiplatelet
agent1. It has been reported to reduce risks in patients with acute
coronary syndrome undergoing coronary stenting2 and have
beneﬁts to patients with percutaneous coronary intervention3.
Clopidogrel is approved for the reduction of atherosclerotic events
in patients with stroke, myocardial infarction, cardiovascular
disease, and acute coronary syndrome4.
Clopidogrel is primarily metabolized to an inactive car-
boxylic acid derivative, generated by hydrolysis, and to the
pharmacologically active metabolite (AM) via an inactive
2-oxoclopidogrel by a two-step cytochrome P450 oxidation
process5. Analytical methods for determining inactive carboxyl
metabolite6 and the active metabolite5 have been reported. Also,
an LC–MS/MS method for determining the parent compound
clopidogrel has been established and validated7,8. The main
application of such methods was the development of generic
formulations of clopidogrel according to bioequivalence regu-
lations (EMEA, FDA, etc.); these norms require the measure-
ment of the parent compound, whenever possible from the
analytical point of view, since this is the most sensitive to
formulation problems9,10.
Our laboratory developed and validated an analytical method
to quantify clopidogrel in plasma samples of subjects enrolled
in bioequivalence studies in 2010. The FDA bioanalytical
validation rules (2001) were followed. Preliminary use of this
method with clinical samples revealed that supernatant fractions
following a methanol precipitation step demonstrated increased
clopidogrel levels following storage at ambient temperature,
subsequently shown to be due to back-conversion from a
metabolite. This back-conversion is further discussed in the result
and discussion sections. Presently, a new method to determine
clopidogrel in plasma was validated with application of an online-
SPE system Symbiosis (Spark, Holland). The back conversion
problem was solved by directly injecting real samples into the
online-SPE system and automatically loading into LC–MS/MS
system. In order to evaluate and monitor the back conversion of
clopidogrel, pooled real samples (at two concentration levels) were
prepared and analyzed in the validation process. In the sample
analysis, one level of pooled real samples was prepared and
analyzed to further ensure the settlement of the back conversion of
clopidogrel.
The online-SPE method is presented in this paper, together with
discussion of validation procedures. The method was successfully
applied in the bioequivalence study of single administration of
75 mg dose clopoidogrel tablets.2. Materials and methods
2.1. Chemicals and reagents
Clopidogrel hydrogensulfate standard was obtained from
Dr. Reddy's Laboratory Co., Ltd. (Hyderabad, India). The
internal standard (IS, clopidogrel-d4 hydrogensulfate) was
purchased from TRC (Canada). HPLC-grade acetonitrile was
from Tedia Company Inc. (Fairﬁeld, USA) and formic acid
was from DIKMA Company Inc. (Lake Forest, USA).
Acetate ammonium and dimethylsulfoxide (DMSO) were of
analytical grade.2.2. Stock and working standard solutions
The stock solutions of clopidogrel and IS (clopidogrel-d4) were
prepared in 50% DMSO. Hydrogensulfate of both clopidogrel and
IS were coverted to calculate the real concentrations of clopidogrel
and IS.
All of stock solutions were stored at 30 1C and the stock
solutions of clopidogrel were used up to 1 month from preparation.
Working standard solutions were prepared in 50% DMSO. Work-
ing dilutions from stock solutions of the analyte were freshly
prepared when needed.
2.3. Calibration curves and quality control samples preparation
The concentrations ranged from 10 to 10,000 pg/mL for clopido-
grel. The calibration points were 10, 20, 100, 500, 1000, 5000,
10,000 pg/mL. Working standard solutions of calibration standards
(0.1, 0.2, 1, 5, 10, 50 and 100 ng/mL) were prepared in 50%
DMSO. Working solutions of calibration standards were then
spiked into human plasma (1/9, v/v).
Pooled real samples were used as additional real sample quality
control (QC) in both validation and sample analysis. Two levels of
pooled real samples were used to monitor the back conversion of
clopidogrel (one level in absorption phase and one level in
elimination phase). The concentration of real sample QC was
determined by the ﬁrst validation run. The concentration value of
real sample QC in validation run 1 was used to calculate accuracy,
precision and bias of real sample QCs in the following validation
runs. In the sample analysis, one level of real sample QC was
applied. The concentration of real sample QC in sample analysis is
analyzed before sample analysis was started. The value of real
sample QC was used to calculate accuracy, precision and bias in
the following sample analysis process.
2.4. Clopidogrel isolation from plasma samples
Aliquots of plasma (100 μL) were transferred in 1.5 mL poly-
propylene tubes. Working solution of IS (10 ng/mL, clopidogrel-d4
in 50% DMSO, 10 μL) was added. Samples were vortexed for
30 s. Aliquot (100 μL) of plasma samples with IS were aspirated
and transferred in 96-well plates and analyzed by online SPE–LC–
MS/MS as described below.
2.5. Liquid chromatography system
In preliminary test, the liquid chromatography system Shimadzu
Prominence (Shimadzu, Kyoto, Japan) was equipped with two
LC-20AD pumps, a DGU-20A3 vacuum degasser, a SIL-HTC
autosampler, a CTO-20AD column oven and a controller module.
In order to solve the back conversion problem of clopidogrel, an
online SPE system (Symbiosys, Spark, Holland) was used. The
system integrated the liquid chromatography unit with solid phase
extraction unit including binary pumps (in this method, isocratic
pump was used), an autosampler, an automatic cartridge exchanger
unit, two high pressure dispensers and a column oven.
The chromatographic separation was achieved on an Eternity-
2.5-C18-UHPLC column (50 mm 2.1 mm, 2.5 μm, Kromasil,
Sweden) with a C18 guard column (4 mm 3 mm, 5 μm, Phe-
nomenex, USA). The column oven temperature was set at 45 1C.
The samples were kept at 4 1C in an autosampler. The mobile
phase consisted of 0.04% formic acid, 3 mmol/L ammonium
Figure 1 Peak focus mode in clopidogrel method11.
Table 1 Online SPE condition for clopidogrel method.
Procedure Reagent Flow rate
(μL/min)
Volume
(μL)
Conditioning Acetonitrile 5000 1000
Equilibration Water 5000 2000
Sample load Water 2000 1000
Extraction 1 25% Acetonitrile
in water
5000 1000
Extraction 2 25% Acetonitrile
in water
5000 500
Cartridge wash Acetonitrile 5000 1000
HPLC–MS/MS to determine clopidogrel in human plasma 57acetate in acetonitrile/water (65:35, v/v). Mobile phase at the ﬁrst
minute was set at 0.15 mL/min, and ﬂow rate returned to 0.35 mL/min
in the remaining 4.5 min. Besides, a peak focusing mode was used
to obtain the acquire sensitivity. Peak focus mode included mobile
phase and focus reagent (water). Focus reagent was set at 200 μL/
min for 1 min, propelling by a high pressure dispenser detailed in
Fig. 111.
2.6. Online SPE conditions
The online-SPE cartridge was HySphere C8 EC-SE (10 mm 2.0
mm, 10 μm). In the automatic exchanger unit of Symbiosis
System, there were two positions. Position 1 was for the sample
pretreatment. After SPE procedures, cartridges were transferred
into position 2. The pretreated samples were ﬁnally eluted by
mobile phase into the analytical column and MS. When the former
sample was analyzed, the latter sample could be prepared on SPE
simultaneously. The detailed online SPE condition was listed
in Table 1.
2.7. Mass spectrometry system
Analytical procedures were carried-out on Applied Biosystems-
Sciex (Toronto, Ontario, Canada) mass spectrometers. In the
preliminary experiment, a triple-quad linear ion trap model AB
Sciex 5500 QTrap instrument was used. For the second method, a
triple-quad model AB Sciex 5500 mass spectrometry was used
with the online SPE system. Both mass spectrometries wereequipped with electrospray ion source. The ion transitions were
monitored on m/z 322.1-212.1 amu for clopidogrel and m/z
326.1-216.1 amu for IS (clopidogrel-d4). The data were acquired
and processed using Analyst 1.5.1 software package.
The eluent from the HPLC column was diverted into waste for a
short period (2 min) using a computer controlled switching valve
and in 2.1 min, the eluent was loaded into the mass spectrometer.
The acquisition duration was 5.5 min.
2.8. Validation procedures
The validation of the online-SPE HPLC–MS/MS method for the
determination of clopidogrel in plasma samples was performed in
accordance with FDA rules12. In the method validation, real QC
samples were introduced into the method validation and sample
analysis process as additional QC to monitor the back conversion
of clopidogrel.
The method was validated by testing lower limit of quantiﬁcation
(LLOQ) and carryover, speciﬁcity, endogenous interference, linearity,
intra- and inter-assay precision and accuracy, matrix effect and
recovery, and sample stability (back conversion) following the FDA
guidance on bio-analytical method validation12.
The analytical range to be validated was chosen on the basis of
the expected plasma concentrations13,14. Spiked plasma samples
were prepared for calibration curves (7 points) and quality controls
(5 different levels) as described in the previous section. The
following validation tests were carried out.
2.8.1. Sensitivity and carryover
LLOQ was the limit for precisely quantifying the compound.
Signal–noise ratio (S/N) should be at least 6:1. The carryover was
evaluated by injecting blank sample after ULOQ sample of the
calibration standard. Carryover in the blank sample following the
ULOQ should not be greater than 20% of the LLOQ for
clopidogrel and 5% for the IS.
2.8.2. Speciﬁcity
Speciﬁcity was to evaluate by analyzing blank human plasma from
six different sources. QC samples at LLOQ, low middle and high
concentrations were analyzed on six separate sources with three
replicates at each concentration per occasion to determine inter-
ference from difference sources matrix. The average accuracy and
Figure 2 Advance method development (AMD) mode to text extraction recovery11.
Figure 3 Theoretical two peaks generated by two cartridges
tandem mode.
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points, should be within 715%, except for the LLOQ (720%).
2.8.3. Endogenous interference
Interference from endogenous material was accessed by analyzing
blank human plasma from six different sources. The peak area of
interference peak should not exceed 20% of the peak area of
LLOQ. The result was to demonstrate the lack of chromatographic
interference from blank endogenous plasma components.
2.8.4. Linearity, regression model, precision and accuracy
The linearity of clopidogrel was evaluated over the range of 10–
10,000 pg/mL. Calibration curves were prepared in replicate
(n¼2) and analyzed. The accepted correlation coefﬁcient (r),
obtained using the appropriate regression model giving the best
ﬁtting in the whole range of tested concentrations, must be40.99,
with precision and accuracy, for the back-calculated concentrations
of the calibration points, within 715%, except for the LLOQ
(7 20%).
2.8.5. Intra- and inter-assay precision and accuracy of QC
QCs at ﬁve concentration levels: LLOQ, low, middle, high and
dilution QC (10, 25, 1500, 8000 and 40,000 pg/mL), were analyzed
to evaluate intra- and inter-assay precision and accuracy of the method,
with six replicates for each of the three consecutive batches. The
dilution factor for dilution QC was 5, which meant that the concentra-
tion of spiked dilution QC was 40,000 pg/mL and it was diluted for
5 fold by blank plasma. Precision was expressed as CV (%) for
replicate measurements and accuracy (%) by the percentage of
deviation between nominal and calculated concentrations.
2.8.6. Extraction recovery and matrix effect
In this study, the analytical system performed online pretreatment. The
blank treated samples (supernatant or reconstituted matrix) could not be
obtained. Therefore, un-extracted peak area value could not be
obtained. Extraction recovery was tested according to the methods
provided by instrument vendor. The mechanism can be illustrated in
Fig. 211. In the test of extraction recovery, two cartridges (Cartridge
1 and 2) were placed on position 1 and 2 to form a tandem mode. QC
samples (25, 1500 and 8000 pg/mL, n¼6 for each) were analyzed.
Every sample analysis could obtain two peak areas as illustrated inFig. 3. A1 was obtained from cartridge 1 and A2 was obtained from
cartridge 2. Recovery (%)¼A1/(A1þA2) 100.
Matrix effect could be evaluated by analyzing plasma QC
samples (25, 1500 and 8000 pg/mL, n¼6 for each) and IS
samples. These peak areas were recorded as A(L), A(M), A(H).
Then, chemical QCs were prepared by spiking the same nominal
concentration of clopidogrel (25, 1500 and 8000 pg/mL, n¼6 for
each) and IS using mobile phase as blank matrix. The peak area
was recorded as AC (L), AC (M), AC (H) and AC (IS). The matrix
effect was evaluated by formula: Matrix effect (%)¼A/AC 100.
2.8.7. Sample stability and back conversion test
Pooled real samples were prepared to evaluate and monitor the
back conversion. Pooled real sample QC was prepared by pooling
the 0.75 h point and 2 h point real samples. Two levels of real
sample were prepared as SQC-1 and SQC-2. Therefore, ﬁve
concentrations of stability concentrations (low, middle, high,
SQC-1 and SQC-2) were used for evaluation of sample stability
and back conversion.
Stability studies in plasma samples were conducted at ﬁve QC
levels (low, middle, high, SQC-1 and SQC-2) in different storage
HPLC–MS/MS to determine clopidogrel in human plasma 59conditions. Bench-top stability was evaluated by placing the QC
samples at room temperature for 24 h. The freeze-thaw stability
was evaluated by analyzing the stability samples at ﬁve concen-
tration levels (n¼3) after three cycles from 30 1C to room
temperature. The autosampler stability was tested by keeping the
spiked and pooled stability samples in autosampler at 4 1C. Long
term stability was tested by analyzing stability samples (5 levels,
n¼3) in every 7 days since Day 0. The stock solution stability of
clopidogrel and the IS were tested for 24 h at room temperature
and 3 months at 30 1C, comparing peak areas to those of freshly
prepared solutions.
2.9. Pharmacokinetic assessment
The method was applied to determine the plasma concentrations of
clopidogrel from 48 Chinese young healthy subjects for a
bioequivalent study of two clopidogrel tablets. The concentration
level was evaluated in the range of 24 h. Before sample analysis,
one level of real sample QC was prepared by mixing 0.25–4 h
back-up real samples. Also, sample analysis QC samples (low,
middle and high) were also prepared before sample analysis. Four
levels of QC were tested before sample analysis to conﬁrm their
accuracy within 715% of nominal concentrations. The study was
approved by the Ethics Committee of Shanghai Xuhui Central
Hospital. Each subject was informed of the purpose of the study,
and informed consent forms were obtained.3. Results and discussion
3.1. Selection and optimization of analytical conditions
The molecular ion corresponding to 35Cl (322.1) was chosen as
precursor ion for clopidogrel in the MRM method used for
quantiﬁcation, while for clopidogrel-d4, the molecular ion of
326.1 was preferred. Product ion spectrum of clopidogrel was
similar to that reported15. For clopidogrel-d4, four isotopes labeled
IS had a good selectivity, which could be demonstrated by
interference test in the following paragraph. Therefore, we chose
216.1 amu as product ion of clopidogrel-d4. The detailed mass
spectrometry parameters are listed in Table 2.
3.2. Optimization of online-SPE condition
Clopidogrel is a medium polarity molecule. We evaluated C8 and
C18 cartridges. The retention times were similar between two
types of cartridges. C18 cartridges have a slightly stronger
retention but the background signal and interference is also
stronger than C8 cartridge. After we evaluated the S/N ratio, we
chose the C8 cartridge.Table 2 Mass spectrometry parameters for clopidogrel
method.
Ion source Turbo V™
Source temperature (1C) 550
Curtain gas (psi) 30
GS1 (psi) 70
GS2 (psi) 60
Ionspray voltage (V) 1800SPE process includes activation, equilibration, sample loading,
sample wash and elution. In the equilibration step, we evaluated
1000 μL and 2000 μL water. Water 1000 μL was not able to replace
acetonitrile after previous step, which could decrease the recovery of
cartridge. Finally we selected 2000 μL water in equilibration. In the
sample wash step, we evaluated 5%–50% acetonitrile in water. Matrix
effect of 5% aqueous acetonitrile was strong and recovery of analyte
decreased in 50% aqueous acetonitrile. Therefore, we chose 25%
aqueous acetonitrile as the sample wash solvent. We also discovered
that two sample washes could minimize the matrix effect, so we
applied two sample wash steps.
In this analytical method, we applied peak focus mode to
optimize the peak shape. In this mode, another ﬂow path was
introduced after SPE elution, which is similar to gradient elution.
We applied water 200 μL as peak focus solvent in this method to
optimize the peak shape. Mobile phase 150 μL was used to elude
the sample from SPE cartridge.
3.3. Sensitivity and carryover
Typical MRM chromatograms for clopidogrel obtained in blank,
LLOQ and ULOQ samples are presented in Fig. 4. In the chromato-
grams of LLOQ, the S/N ratio is 410, demonstrating adequate
sensitivity as well as a background free from interfering signals.
The carryover of clopidogrel was less than 20% of average peak
area of LLOQ. The carryover of IS (clopidogrel-d4) was less than
1% of average peak area.
3.4. Speciﬁcity and endogenous interference
Six different sources blank plasma were used to prepared LLOQ,
low, middle and high (n¼3) to test the speciﬁcity of clopidogrel.
The average accuracy of clopidogrel was 96.27%–101.1%, with
CV of less than 2%. Thus, this method has good speciﬁcity with
little inﬂuence of the matrix from different sources.
Six different sources of blank plasma (n¼3) were used for
testing the endogenous interference. There were no interfering
peaks at either the clopidogrel or the IS retention time.
3.5. Linearity, accuracy and precision
Calibration curves were linear (1/x2 weighted regression model)
for the analytical method, with correlation coefﬁcients40.99. The
method for clopidogrel was both accurate and precise for the intra
and inter batches for each level (LLOQ, low, middle, high,
dilution). The intra-batch precision CV of the assay was no more
than 4% at four concentration levels of the QC samples, the CVs
for inter-batch precision were no more than 6%. The inter- and
intra-batch accuracies of the assay ranged from 90.15%–103.7%
and 94.79%–102.7%, respectively. The mean precision and
accuracy of ﬁve levels are listed in Table 3.
3.6. Extraction recoveries
The average extraction recoveries of clopidogrel were 99.58%–
99.91% with CV of less than 2%. In this study, an online-SPE
system was used to solve the sample back conversion problem,
which is discussed in the next section. The test method of
extraction recoveries in this study was different from the routine
practice.
Figure 4 Representative LC–MS/MS chromatograms for clopidogrel and IS (clopidogrel-d4) in human plasma. (A) Blank human plasma;
(B) LLOQ of 10 pg/mL of and IS; (C) ULOQ of 10 ng/mL of and IS; (D) human plasma sample.
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with two steps. First, clopidogrel was quantiﬁed by analyzing
normal spiked QC samples (25, 1500 and 8000 pg/mL) and IS
samples. Each was with six duplicates. These peak areas were
recorded as A(L), A(M), A(H). The recovery was calculated by
comparing the peak areas of extracted from QC samples with those
of spiked concentrations. The spiked concentrations were recorded
as A0(L), A0(M), A0(H). Extraction rates were calculated according
to the equation: Extraction rate (%)¼A/A0  100.
In the online-SPE tandem LC–MS/MS method, the chemical
clopidogrel cannot be added to the SPE processed blank samples.
Therefore, the routine practice was not feasible in this study.
Because of the introduction of online-SPE system, extraction
recovery was made up of two parts: sample pretreatment recovery
and SPE cartridge recovery. In this study, adding IS was the only
step of sample pretreatment and plasma was directly injected into
the system, therefore, sample pretreatment recovery was 100%.
Cartridge recovery could be evaluated by using advanced method
development (AMD) mode, which was recommended by the
instrument vendor, Spark Holland.
In AMD mode, the former paralleled two cartridge positions
(left and right) switched to be the tandem positions to test the
extraction recovery. The spiked QC samples were loaded into the
left cartridge to be puriﬁed and concentrated. Wash solvents ﬁrst
ﬂushed through left cartridge and then were loaded into the second
cartridge (right position) (Fig. 2). Finally, the ﬁrst and second
cartridges were sequentially eluted by the mobile phase, and
theoretically two peaks could be observed (Fig. 3). The peak area
of ﬁrst peak represented the absorbing amount of the analyte
(clopidogrel) and IS on the ﬁrst cartridge. The second peak
signiﬁed the amount of analyte not being absorbed by the ﬁrst
cartridge. Therefore, Recovery (%)¼A1/(A1þA2) 100.
3.7. Matrix effect
The mean matrix effect of clopidogrel (3 levels) and IS were
74.01%, 67.91% and 81.23% for clopidogrel and 72.63% for ISTable 3 Precision and accuracy for determination of clopid
3 consecutive runs).
Nominal conc.
(pg/mL)
Intra-assay (n¼6)
Accuracy (%) CV
10 99.43 3.8
25 98.22 2.7
1500 100.4 0.3
8000 98.90 0.4
40,000 (dilution) 101.0 1.2
Table 4 Back-conversion test of pooled real samples (two level
measurement (r.t. for 24 h, 4 1C for 60 h and freeze–thaw 3 cycles).
Back-conversion test SQC-1 (Mean) pg/mL
R.t. for 0 h 224.3
Auto-sampler (4 1C) for 60 h 224.6
Freeze–thaw stability (three cycles) 219.8
R.t. for 24 h 205.7with RSD less than 3% indicating mild ion suppression. The
matrix effect of clopidogrel and IS was similar with each other.
3.8. Sample stability and back conversion test
In order to evaluate sample stability and back conversion, in this
study, we used pooled real samples as real sample QCs (two
levels: SQC-1 and SQC-2) and routine spiked QC samples (low,
middle and high) to evaluate the sample stability and back
conversion problem. The result showed that clopidogrel was stable
in ambient temperature for 24 h for both spiked QC samples and
real sample QCs with bias of less than 9%. Freeze–thaw stability
showed that the bias of the three cycles was less than 5%. Samples
(low, middle, high, SQC-1 and SQC-2) in antosampler (4 1C) were
stable for at least 60 h. The detailed back conversion test result
was shown in Table 4. Long-term stability (ﬁve levels) results
showed that clopidogrel was stable at 30 1C for at least 77 days
(Table 5).
At ﬁrst, we established and validated a protein precipitation
method and an LC–MS/MS analyitical method for quantiﬁcation
of clopidogrel. The QC samples in three levels (low, middle and
high) passed all the validation criteria according to FDA 2001
guidelines. But in the process of incurred sample reanalysis, we
discovered the back conversion problem. We discovered that the
concentration in the supernatant of real samples increased remarka-
bly after it was stored in room temperature for 16 h compared with
the ﬁrst analysis (Table 6). But the concentration of spiked QC
samples was stable in different conditions.
The back conversion problem occurred after plasma samples
were pretreated by protein precipitation. Online-SPE system
guaranteed that the automatic pretreated samples were directly
injected into LC–MS/MS systems, which left no time gap for
pretreated samples storage before sample analysis. Besides, we
prepared IS by 50% DMSO water and prohibited the use of
methanol in the analytical method. The concentration of clopido-
grel in real clinical sample was stable in the existence of 50%
DMSO water.ogrel in human plasma (intra-day: n¼6; inter-day: n¼18,
Inter-assay (n¼18)
(%) Accuracy (%) CV (%)
70 94.79 5.232
46 97.09 4.536
078 101.0 2.383
764 99.74 0.9858
09 102.7 2.199
s). Mean bias of the ratios concentration after storage vs. ﬁrst
CV (%) SQC-2 (Mean) pg/mL CV (%)
0 1315 0
0.1337 1.326 0.8365
1.977 1322 0.5577
8.279 1.221 7.123
Table 6 Back conversion of clopidogrel in real samples after
methanol precipitation.
Sample
No.
Supernatant at r.t.
(pg/mL)
Supernatant at r.t. after
16 h (pg/mL)
1A7 331.5 2267
2A7 253.2 2954
3A7 634.9 1725
4A7 3018 7143
Figure 5 Mean dose-time curve of clopidogrel after an oral admin-
istration of two brand tablets of 75 mg clopidogrel tablets in two
formulations to 48 healthy male volunteers.
Table 5 Long term stability of ﬁve concentration levels (low, middle, high, SQC-1 and SQC-2) for 77 days at 30 1C. Mean bias of the
ratios concentration after storage vs. ﬁrst measurement.
Nominal conc. (pg/mL) Time interval (day)/CV (%)
0 day 21 days CV (%) 49 days CV (%) 77 days CV (%)
25 25.39 23.49 7.482 26.17 3.045 23.79 6.327
1500 1499 1487 0.7783 1482 1.112 1466 2.201
8000 7888 8041 1.931 7754 1.699 7590 3.778
224.3 (SQC-1) 224.3 209.2 6.733 208.3 7.105 205.0 8.390
1315 (SQC-2) 1315 1280 2.662 1245 5.323 1232 6.286
Gangyi Liu et al.62In this study, the real samples, clopidogrel were very unstable in
existence of methanol, which was in agreement with the data
reported by Havard et al.16. Some research papers explained this
phenomenon by the back conversion of an unknown metabolite
(cloppidogrel carboxylic acid acyl glucuronide)8. Therefore, beside
the routine spiked QC samples, pooled real samples were prepared
by mixing 0.75 h time point real samples and 2 h time point back-
up real samples and naming as SQC-1 and SQC-2. These two real
sample stability QCs have the same acceptance criteria with spiked
QC: the average bias of back-calculated concentrations of real
sample QC should be within 715% comparing with 0 h. We
applied real clinical sample QC to monitor the back conversion,
and the concentration of clopidogrel was stable throughout the
validation and sample analysis.For clopidogrel quantiﬁcation, some research papers reported
methods to control the back conversion phenomenon to an
acceptable extent5,8. But different from the researchers reported,
we validated that clopidogrel in real samples was stable for at least
24 h in room temperature and back conversion was within 79%
of the ﬁrst measurement. Silverstro et al.8 reported that clopidogrel
in real plasma samples increased by 50% at room temperature for
3 h comparing with ﬁrst measurement, which was not agreement
with our result. In our validation process, we evaluated back
conversion ratio of 0, 4 and 24 h at room temperature using two
level pooled real samples as SQC-1 and SQC-2. The back
conversion ratios were 1.739% and 1.766% at 4 h, respectively.
After 24 h in room temperature, the back conversion ratios were
8.279% and 7.123%, respectively. Therefore, back conver-
sion was not occurred in real plasma samples in room temperature.
As for the reason of this opposite result, we believe that Silverstro
et al. in their method, used methanol as precipitation reagent. Back
conversion was very fast in the methanol environment, so slight
differences of sample preparation duration might trigger the back
conversion and concentration increase.
Therefore, low temperature was not mandatory in the sample
preparation process, which was opposite to reported8. The method
with application of online-SPE system can solve the back
conversion problem with simple sample preparation procedures.
Back conversion and stability problem was evaluated throughout
the whole validation process with good result.
3.9. Pharmacokinetic assessment
Mean pharmacokinetic curves calculated from plasma samples
with volunteer orally treated with two brand tablets of clopidogrel
(75 mg) are displayed in Fig. 5. Sample analysis QC as well as real
sample QC met the acceptance criteria in all sample analysis runs.4. Conclusions
An online SPE tandem mass spectrometry method was developed,
validated and used in real sample analysis for determination of
clopidogrel, an antiplatelet agent. An unexpected and scarcely met
back conversion problem was observed in the method develop-
ment phase with methanol precipitation.
The application of online SPE system and the avoidance of
methanol in this method solved the back conversion problem. In
the online SPE tandem mass spectrometry method, plasma samples
were processed by SPE cartridges and automatically loaded into
analytical column.
In the method validation process, pooled real samples (two
levels) were used as real sample QC to evaluate the back
HPLC–MS/MS to determine clopidogrel in human plasma 63conversion in different conditions. Back conversion ratio met the
acceptance criteria of routine spiked QC (within 9%). Real QC
samples were stable for at least 24 h in room temperature, for at
least 60 h in autosampler (4 1C), for at least 77 days in 30 1C.
Three freeze–thaw cycles (from 30 1C to room temperature) did
not affect the concentration values within acceptance criteria.
Since online-SPE system was not applied into formal method
validation process before, extraction recovery, as suggested by
instrument vendor Spark Holland, was evaluated by two parts:
sample recovery and cartridge recovery. In this study, plasma
samples were directly loaded into the system, so the sample
recovery was 100%. Cartridge recovery was assessed by using two
tandem SPE cartridges. Cartridge recovery in this method was
499%.
Linearity, precision, extraction recovery, matrix effects and
stability tests on blank plasma spiked with clopidogrel and stored
in different conditions met the acceptance criteria. During the
sample analysis of the real samples, the pooled real samples
continued followed every sample analysis run with acceptance
accuracy and precision. This online-SPE method was successfully
applied to a bioequivalence study of 75 mg single dose clopidogrel
tablets in 48 healthy male subjects.References
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